Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
This study provides insight into the personal, social and environmental factors that participants report as barriers and facilitators to the adoption of the MIND diet among middle-aged adults living in the UK.
-
Higher MD adherence is strongly associated with better cognitive status and less depressive symptomatology.
-
Self-assessed sensory impairment is independently associated with cognitive decline and incident possible CIND and probable dementia.
Why it matters
In 19,618 older adults, self-reported hearing, visual, and dual sensory impairments were associated with worse cognitive test performance and higher risk of possible cognitive impairment and probable dementia. This observational study shows associations only and does not test whether treating sensory impairment prevents dementia.
-
Dementia reduces a person's ability to perform their activities of daily living and is the leading cause of morbidity worldwide.
Why it matters
This review reports that treating hypertension in middle-aged and older adults without dementia may reduce the incidence of dementia, though only one trial using calcium-channel blockers showed a significant reduction. It calls for further studies on the long-term benefits of antihypertensive treatment.
-
Machine learning has become ubiquitous and a key technology on mining electronic health records (EHRs) for facilitating clinical research and practice.
Why it matters
Unsupervised machine learning models identified latent disease clusters and patient subgroups from electronic health records, including a Delirium/Dementia cohort. This is a method for discovering patterns in health records and does not treat, cure, or prevent Alzheimer's disease.
-
This study will provide evidences to evaluate the efficacy and safety of SMYZD in combination with GBEs in treatment of VaD, as well as the adjuvant role of SMYZD in combination.
Why it matters
This is a study protocol, so no results are available yet on whether Shenmayizhi decoction helps vascular dementia. The trial will compare it as an add-on to Ginkgo biloba extracts in 196 patients over 12 weeks.
-
43/100
As our population ages, therapies increase, and the number of individuals living with advanced PD and related disorders grows, so too does the imperative to recognize and address the palliative care needs of such patients and families.
-
The clinical symptoms of dementia include difficulty with speech, poor short-term memory, and changes in behavior.
Why it matters
This qualitative review examined how people with mild to moderate dementia maintain social connections and manage their social persona. It addresses social support and self-management, not treating, curing, or preventing Alzheimer's disease.
-
No disease-modifying therapy is currently available for Alzheimer's disease, but therapies are in development, and one may become available in the near future.
Why it matters
This analysis argues that because candidate treatments have not reversed dementia, Alzheimer's may need to be prevented rather than cured, with future therapies aimed at early-stage patients such as those with mild cognitive impairment. It estimates about 20 million people over 55 in the EU have mild cognitive impairment and examines whether health systems could handle screening and treatment if such a therapy became available.
-
The national prevalence and incidence of registered dementia diagnoses was 3.0% and 0.5%, respectively.
Why it matters
This study found that dementia diagnosis rates and use of anti-dementia medication varied widely across five regions, indicating unequal access to diagnosis and care. It does not test a treatment or prevention, so it cannot show how to cure or prevent dementia.
-
Proton pump inhibitors (PPIs) are among the most frequently prescribed medications.
Why it matters
This review notes that at least one study has suggested long-term proton pump inhibitor use increases the risk of dementia, among other concerns. It reports a suggested association, not a proven cause, and offers no treatment or cure.
-
Communication for people with dementia and with people with dementia for all persons involved in care (including family members, medical staff and therapists, and members of the community) can be very challenging.
Why it matters
This review explains that language difficulties in dementia come from failing nerve cells and are not the person's fault. It supports adapting how caregivers and staff communicate with people who have dementia, but it does not test any treatment or cure.
-
The increased incidence of seizures and epilepsy in the elderly can be attributed to the increase of age-related and aging-related epileptogenic conditions.
Why it matters
This review describes the epidemiology of epilepsy in aging populations, noting that increased seizures in the elderly can be attributed to age-related conditions including stroke and dementia. It is about epilepsy and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Physical activity has profound impacts on the vasculature in humans.
Why it matters
This review describes how exercise affects blood vessels and notes that exercise plays a role in conditions with a vascular cause, including dementia. It does not report any trial showing that exercise prevents or treats Alzheimer's disease.
-
As a result, NHS data provide a huge and invaluable resource of routinely collected primary (e.g. visits to GP practices) and secondary (e.g. hospital admissions, outpatient appointments, A&E attendances) healthcare data covering near-100% of the population of England.
Why it matters
This paper discusses challenges with patients opting out of NHS data sharing and how this affects small-area health data. It has no findings about treating, curing, or preventing Alzheimer's disease.
-
Globally populations are ageing. By 2050, it is estimated that there will be two billion people aged 60 years or over, of which 131 million are projected to be affected by dementia, while depression is predicted to be the second leading cause of disability worldwide by 2020.
Why it matters
This review reports some evidence linking dietary patterns, particularly the Mediterranean diet, and specific nutrients such as n-3 PUFA, polyphenols, vitamin D and B-vitamins with brain health, with the strongest evidence for folate and related B-vitamins in slowing cognitive decline. It is a review of existing evidence and does not establish that any diet or nutrient prevents dementia.
-
43/100
There are many factors that strongly influence the aetiology, development, and progression of cognitive decline in old age, mild cognitive impairment (MCI), and Alzheimer's disease (AD).
Why it matters
This review discusses how personality traits, mood, and lifestyle factors such as exercise and diet affect the hippocampus and may influence cognitive decline in old age, mild cognitive impairment, and Alzheimer's disease. It offers recommendations but presents no new treatment, cure, or prevention results.
-
One in 8 patients presented with moderate speech timing deficits with a further two-thirds rated as mild or subclinical.
Why it matters
This study described motor speech function in 24 individuals with behavioral variant frontotemporal dementia compared to healthy controls. It found speech was significantly different and correlated with brain regions, but it is about characterizing a different dementia, not treating Alzheimer's disease.
-
Through various manifestations, social inappropriateness is frequently the first clinical sign of a neurodegenerative process, especially in AD and bvFTD, years before noticeable impairment on classical neuropsychological assessment and brain atrophy on imaging.
Why it matters
This review describes how impaired social cognition contributes to inappropriate behaviors in early frontotemporal dementia and Alzheimer's disease. It is about understanding symptoms and does not test any treatment, cure, or prevention.
-
With a rapidly aging population, general practitioners are confronting the challenge of how to determine those who are at greatest risk for dementia and potentially need more specialized follow-up to mitigate symptoms early in its course.
Why it matters
This study produced a practical risk score that gives individualized estimates of a person's chance of developing dementia over 5, 10, and 20 years. It is a prediction tool, not a treatment, so it does not show how to cure or prevent dementia.
-
43/100
Mild cognitive impairment (MCI) occurs along a continuum from normal cognition to dementia.
Why it matters
There are currently no pharmacologic treatments proven to slow or cure progression of mild cognitive impairment to dementia. There is evidence that lifestyle changes such as diet, exercise, and cognitive stimulation may be effective, and reversible causes should be checked once MCI is diagnosed.
-
Consultations appear to reduce acute care use and (potentially) burdensome transitions for dying residents with dementia.
-
Whilst nursing home managers recognise the potential benefits of advance care planning, barriers and challenges create a reluctance to facilitate.
Why it matters
This survey of nursing home managers in the UK found they lacked knowledge of advance care planning and held negative attitudes, with concerns about capacity and perceived lack of benefit to the person with dementia. Managers did not view advance care planning as part of their role, and this lack of ownership affected current practice.
-
Longer age-related decision making latencies may reflect a greater need for working memory and increased self-monitoring in older subjects.
Why it matters
This study used a digital Clock Drawing Test in stroke- and dementia-free participants and found age-related differences in total time to completion, pen stroke count, and higher-order decision making latencies. The authors suggest these latency measures have potential to serve as neurocognitive biomarkers of Alzheimer's disease and other neurodegenerative disorders.
-
Despite major improvements in primary prevention and acute treatment over the last decades, stroke is still a devastating disease.
Why it matters
This review reports that within the first year after a stroke, 7% to 23% of patients develop dementia and 35% to 47% develop mild cognitive disorder. It notes that stroke incidence in young adults is rising and that the absolute number of strokes is expected to increase with the ageing population, highlighting stroke prevention and post-stroke care as important.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Examining annual transitions in healthcare spending among U.S. medicare beneficiaries using multistate Markov models: Analysis of medicare current beneficiary survey data, 2003-2019
- The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee
- Hippocampal volume assessment in temporal lobe epilepsy: How good is automated segmentation?
- Dementia as a predictor of palliative care: Uncovering patient patterns based on German claims data
- Validity and responsiveness of the Minimum Data Set
- Dying from cancer or other chronic diseases in the Netherlands: ten-year trends derived from death certificate data
- Type 1 Diabetes and Incident Dementia
- Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease
- Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study
- Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates